Cyclin A2 Expression as Predictive Biomarker in Muscle-Invasive Upper Tract Urothelial Carcinoma

Urol Int. 2024;108(2):128-136. doi: 10.1159/000536184. Epub 2024 Jan 15.

Abstract

Introduction: The aim was to evaluate the prognostic value of altered Cyclin A2 (CCNA2) gene expression in upper tract urothelial carcinoma (UTUC) and to assess its predictive potential as a prognostic factor for overall survival (OS) and disease-free survival.

Methods: 62 patients who underwent surgical treatment for UTUC were included. Gene expression of CCNA2, MKI67, and p53 was analyzed by quantitative reverse transcriptase polymerase chain reaction. Survival analyses were performed using the Kaplan-Meier method and the log-rank test. For Cox regression analyses, uni- and multivariable hazard ratios were calculated. Spearman correlation was used to analyze correlation of CCNA2 expression with MKI67 and p53.

Results: The median age of the cohort was 73 years, and it consisted of 48 males (77.4%) and 14 females (22.6%). Patients with high CCNA2 expression levels showed longer OS (HR 0.33; 95% CI: 0.15-0.74; p = 0.0073). Multivariable Cox regression analyses identified CCNA2 overexpression (HR 0.37; 95% CI: 0.16-0.85; p = 0.0189) and grading G2 (vs. G3) (HR 0.39; 95% CI: 0.17-0.87; p = 0.0168) to be independent predictors for longer OS. CCNA2 expression correlated positively with MKI67 expression (Rho = 0.4376, p = 0.0005).

Conclusion: Low CCNA2 expression is significantly associated with worse OS. Thus, CCNA2 might serve as a potential biomarker in muscle-invasive UTUC and may be used to characterize a subset of patients having an unfavorable outcome and for future risk assessment scores.

Keywords: Biomarker; Cyclin A2; Overall survival; Upper tract urothelial carcinoma.

MeSH terms

  • Aged
  • Biomarkers
  • Carcinoma, Transitional Cell* / genetics
  • Carcinoma, Transitional Cell* / surgery
  • Cyclin A2
  • Female
  • Humans
  • Male
  • Muscles / pathology
  • Prognosis
  • Retrospective Studies
  • Tumor Suppressor Protein p53
  • Urinary Bladder Neoplasms*
  • Urologic Neoplasms* / genetics
  • Urologic Neoplasms* / surgery

Substances

  • Cyclin A2
  • Tumor Suppressor Protein p53
  • Biomarkers